An observational study in Liver Cirrhosis and Liver Transplant, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Assiut University · Observational
the goal of this observational study is to apply different scores 1. To assess Fatigue, Frailty, Liver Transplant Comorbidity Index and MELD 3.0 in patients with liver cirrhosis awaiting liver transplantation.
2. To evaluate the predictive accuracy of these Scores for the short-term outcomes (early complications, recurrent hospitalization and 3-month mortality). 3. To determine whether using these Scores in the pre-transplant evaluation improves risk stratification compared to MELD score alone.
c. Sample Size Calculation: Sample size was calculated using Epi Info 7. According to the results of a previous study (put ref.), frailty was detected in 17% of patients undergoing liver transplantation. Based on this percentage, with a confidence limit of 5%, a confidence level of 90%, and a design effect of 1, the estimated sample size required is approximately 153 patients.
All patients recruited in the current study will be subjected to the following:
Calculation of - Child Pugh score . Figure (I) Child Pugh score
MELD 3.0 = 1.33 if female+4.56 * loge(bilirubin) + 0.82*137 - Na- 0.24* 137 - Na *loge(bilirubin) + 9.09*loge (INR) + 11.14*loge(creatinine) + 1.85*3.5 - albumin- 1.83*3.5 -albumin *loge(creatinine) +6
4) Anthropometric measurement:
Mid-arm circumference in Centimeters (cm).
5) Fatigue Severity Assessment (via FSS and BFI):
I) Fatigue Severity Scale (FSS):
The FSS is a 9-item scale designed to assess the severity of fatigue and its impact on daily activities. Here are the items:
II) Brief Fatigue Inventory (BFI):
The BFI includes 3 questions on fatigue severity and 6 on how fatigue interferes with daily activities. Here are the items:
Fatigue Severity:
How would you rate your worst fatigue over the past 24 hours?
Interference with Daily Activities:
6) Liver Transplant Comorbidity Index: This index includes the following components and their respective points Factor Points Coronary artery disease 6 Frailty (LFI more than 4.5) 5 HCC 5 Cr more than 1.0mg/dl or on dialysis 3 Diabetes 1
Total score = sum of points.
7) Liver frailty index (LFI): The Liver Frailty Index (LFI) is the most widely validated frailty assessment tool in LT. It integrates three performance-based measures: handgrip strength, the Five-Times Sit-to-Stand Test (5xSST), and balance testing, to generate a continuous score that categorizes patients as robust, prefrail, or frail. The LFI has been shown to independently predict waitlist mortality, hospitalization, and delisting, even after adjustment for MELD score
A) Handgrip strength:
Handgrip strength is measured using a calibrated handheld dynamometer. Three measurements are obtained from the dominant hand, and the maximum value (in kilograms) is used for scoring. Grip strength reflects global muscle strength and correlates closely with sarcopenia and adverse clinical outcomes in patients with Cirrhosis.
B) Five-times sit-to-stand test (5xSST):
The Five-Times Sit-to-Stand Test, also referred to as chair-stand time, is a standardized, performance-based measure of lower extremity muscle strength, power, and functional mobility. The test is simple, rapid, and requires no specialized equipment, making it particularly well suited for use in patients with chronic liver disease and LT candidates. The 5xSST is performed as follows: the patient is seated upright in a chair; on command, the patient stands up fully and then sits down completely; this cycle is repeated five times as quickly as possible. The total time is recorded in seconds.
C) Balance testing:
Balance testing evaluates postural stability and neuromuscular coordination, which are frequently impaired in patients with cirrhosis due to sarcopenia, peripheral neuropathy, and hepatic encephalopathy. Within the LFI, balance is assessed using three hierarchical standing positions that are performed sequentially and held for up to 10 s each.
The three components of the LFI are combined using a validated formula: LFI = (0.330 ×sex-adjusted grip strength in kg) + (0.529 × 5xSST in seconds) + (0.040 × balance time in seconds) + 6.
(calculator available at http://liverfrailtyindex.ucsf.edu).
7.Sarcopenia assessment will be done for those prepared for transplantation: Definition of sarcopenia is based on: -
Bioimpedance analysis-skeletal muscle index (BIA-SMI) with cut-offs of \< 8.87 kg/m2 for men and \< 6.42 kg/m2 for women . According to guideline for European working group on sarcopenia in older people (EWGSOP, the Sarcopenia Working Group) sarcopenia identification was based on both low muscle mass and strength using CT-SMI and hand grip strength
Imaging for assessment of Sarcopenia using:
Computed tomography (CT scan):
The CT scanner differentiated body tissues; organs, adipose, skeletal muscle and bone, water and air based on tissue-specific attenuation values such as SM (-29, +150) and adipose tissue (-190, -30). These attenuation values were reported in Hounsfield Units (HU) named after Sir Godfrey Newbold Hounsfield, the scientist and electrical engineer who invented the CT scanner .The L3 region contains the spinal vertebrae, intestine, kidney and liver, in addition to visceral adipose, subcutaneous adipose and seven muscle groups; the psoas, erector spinae, quadratus lumborum, transversus abdominus, external and internal obliques and rectus abdominus
Step-by-step Guidelines for analyzing a single cross-sectional image:
A) Extraction of CT images: The electronic medical record was assessed to determine if the patient of interest had a CT study that included the L3 region during the desired time interval. Once the CT study had been verified, the patient medical record number, CT study type, scan date and storage device (if transporting images) was provided to the radiologist .
B) Technique for assessment of waist circumference (WC) and skeletal muscle (SM) area Once the L3 image was obtained and determined to be of good quality, the following CT imaging protocol was used for assessment of waist circumference (WC) and skeletal muscle (SM) area at the L3 region.
Computed tomography-based assessment at the level of the third lumbar vertebra (L3) is widely regarded as the reference standard for quantitative muscle assessment in patients with cirrhosis and LT candidates. CT uses tissue-specific X-ray attenuation values, expressed in Hounsfield units (HU), to distinguish skeletal muscle, adipose tissue, and bone .Commonly used CT-derived metrics include the psoas muscle area (PMA), psoas muscle index (PMI), and skeletal muscle index (SMI), the latter typically expressed as cross-sectional area divided by height squared (cm²/m²)
Abdominal ultrasound (US):
Abdominal ultrasound examinations were performed with the subject in the supine position using a 3.75-MHz convex Ultrasound probe. After the routine screening for the abdomen, a transverse scan at the right groin area demonstrated a cross-sectional view of the right iliac artery and vein, which was used as the landmark to detect the iliopsoas muscle located outside the vessels . The iliopsoas muscle area was measured by manual tracing on the image. The iliopsoas muscle index (IP index) was determined by the muscle area divided by the square of height (m2) .
Bioimpedance analysis (BIA) involved passage of a small AC electrical current through the body. As current was conducted by body water, impedance was inversely related to total body water, thus allowing calculation of total muscle mass, which was the largest water-rich tissue in the body .Body composition was assessed with bioimpedance analysis (BIA) using Body Composition Analyzer Fat free mass was measured by BIA and skeletal muscle mass (SMM) was calculated by the following equation: SMM (kg) = 0.566 x FFM (fat free mass) Skeletal muscle mass index (SMMI) was calculated as skeletal muscle mass (kg) /height (m)2.
1,298 studies on the registry are indexed under Liver Cirrhosis; 338 are open to participants now.
This study's planned enrollment of 153 is below the median of 171 across 526 observational studies indexed under Liver Cirrhosis.
Browse Liver Cirrhosis studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
cirrhotic patients awaiting transplantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients with liver cirrhosis (whatever the etiology) eligible for liver transplantation above the age of 18.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Waitlist morbidity and Mortality of liver transplantation
* Risk of early complications, rehospitalization and death while awaiting transplantation. 2\. Post-Transplant Survival for liver transplant recipients * 3- month survival (short-term outcome). Mortality hazard ratios associated with frailty, comorbidities, and MELD 3.0
Time frame: 1.5 years
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 15 months is below that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.